6 completed, 2 terminated. 3 Phase 3, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow sucroferric oxyhydroxide: new trials by email Literature Review of sucroferric oxyhydroxide trials Research Report on sucroferric oxyhydroxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women Iron Carboxymaltose, Iron Sucrose Injection - Iron Deficiency Anemia (IDA), Pregnancy | Phase 4 | Completed | CMH Multan Institute of Medical Sciences | 60 | 2024-02-01 | 2025-04-06 |
| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet - Smallpox | Phase 4 | Completed | SIGA Technologies | 44 | 2022-06-08 | 2026-09-11 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| PA21 Safety and Efficacy in Adult Chinese Subjects PA21, sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 286 | 2018-08-31 | 2021-06-02 |
| Velphoro and Impact on the Oral Cavity and Gut Microbiome Velphoro, saliva collection, Supragingival biofilm collection - Hyperphosphatemia | Terminated | RWTH Aachen University | 22 | 2018-02-28 | 2020-11-25 | |
| The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum low-dose sucroferric oxyhydroxide, high-dose sucroferric oxyhydroxide - Endstage Renal Disease | Phase 2 | Completed | Prim. Priv. Doz. Dr. Daniel Cejka | 40 | 2017-06-09 | 2019-07-22 |
| A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia PA21 (Velphoro®), Calcium Acetate (Phoslyra®) - Hyperphosphatemia | Phase 3 | Terminated | Vifor Fresenius Medical Care Renal Pharma | 85 | 2016-05-26 | 2019-09-10 |
| Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD) sucroferric oxyhydroxide - Hyperphosphatemia | Completed | Vifor Fresenius Medical Care Renal Pharma | 1400 | 2016-04-06 | 2019-10-01 |
Hyperphosphatemia (5) · Anemia, Iron-Deficiency (1) · Renal Insufficiency, Chronic (1) · Smallpox (1)
Vifor Fresenius Medical Care Renal Pharma (3) · Ardelyx (1) · CMH Multan Institute of Medical Sciences (1) · Prim. Priv. Doz. Dr. Daniel Cejka (1) · RWTH Aachen University (1) · SIGA Technologies (1)
Germany (3) · United States (3) · France (2) · Austria (1) · China (1) · Greece (1) · Italy (1) · Lithuania (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1) · United Kingdom (1)
Daniel Cejka, Dr. (1) · David P Rosenbaum, PhD (1) · Dennis Hruby, PhD (1) · Hou Fanfan, MD (1) · Larry A Greenbaum, MD; PhD (1) · Nidda Ya Consultant, FCPS (1) · Sebastian Walpen, Dr. (1)